These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18140885)

  • 1. [A new synthetic anticoagulant, the ethyl ester of dioxycoumarinyl-acetic acid or tromexan].
    BICKEL G; DELLA SANTA R
    Rev Med Suisse Romande; 1949 Sep; 69(9):545-58. PubMed ID: 18140885
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic value of a new anticoagulant: the ethyl ester of di-3,3'-(4-oxycoumarinyl) acetic acid].
    LIAN C; SIGUIER F; WELTI JJ; COBLENTZ B; NEDEY ; BREYNAERT
    Sem Hop; 1951 May; 27(35):1511-22. PubMed ID: 14866256
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacological properties and physiological effects of a new anticoagulant: the ethyl ester of di-3,3'-(4-oxycoumarinyl) acetic acid].
    LIAN C; SIGUIER F; WELTI JJ; PIETTE M; POULLAIN P; PHILIPPON J
    Sem Hop; 1951 May; 27(35):1505-11. PubMed ID: 14866255
    [No Abstract]   [Full Text] [Related]  

  • 4. [Iatrogenic jaundice. Observation of a case following administration of the ethyl ester of 4-4'-dioxycoumarinyl acetic acid (Tromexan)].
    Miracco A; Orlando V
    Riforma Med; 1965 Aug; 79(32):878-9. PubMed ID: 5850868
    [No Abstract]   [Full Text] [Related]  

  • 5. [A new synthetic anticoagulant; Tromexan (G 11705)].
    DELLA SANTA R
    Schweiz Med Wochenschr; 1949 Mar; 79(9):195-206. PubMed ID: 18115607
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experiences with the anticoagulant, ethyl biscoumacetate (N.N.R.).
    BARKER NW; ESTES JE; MANN FD
    Proc Staff Meet Mayo Clin; 1951 Apr; 26(9):162-7. PubMed ID: 14827945
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tromexan and marcoumar in anticoagulant therapy; micromethod for determination of prothrombin-proconvertin activity].
    IVERSEN T
    Ugeskr Laeger; 1955 Jul; 117(27):873-8. PubMed ID: 13256759
    [No Abstract]   [Full Text] [Related]  

  • 8. The coagulation defect caused by tromexan therapy.
    DOUGLAS AS
    Clin Sci; 1955 Nov; 14(4):601-13. PubMed ID: 13270444
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of tromexan and dicumarol on clotting time and prothrombin index].
    KRISTENSON A
    Nord Med; 1951 Jul; 46(29):1102-4. PubMed ID: 14863696
    [No Abstract]   [Full Text] [Related]  

  • 10. Mode of action of tromexan.
    HUNTER RB; TUDHOPE GR
    Lancet; 1953 Apr; 1(6765):821-3. PubMed ID: 13036185
    [No Abstract]   [Full Text] [Related]  

  • 11. [Experiences with Tromexan, a new anticoagulant of the Dicumarol type].
    DEUTSCH E
    Schweiz Med Wochenschr; 1949 Oct; 79(42):1010-5. PubMed ID: 15393257
    [No Abstract]   [Full Text] [Related]  

  • 12. Control of ethyl biscoumacetate (tromexan) therapy by standardized clotting time of whole blood.
    MAYER GA; CONNELL WF
    Can Med Assoc J; 1957 Nov; 77(10):930-8. PubMed ID: 13479846
    [No Abstract]   [Full Text] [Related]  

  • 13. [A case of ingestion of ethyl ester of bis-4-oxycoumarinyl acetic acid (tromexan) in suicide attempt].
    CATALANO V; NAVAZIO F
    Prog Med (Napoli); 1956 May; 12(9):274-5. PubMed ID: 13336168
    [No Abstract]   [Full Text] [Related]  

  • 14. [Experiences with thrombocid, dicumarol and tromexan in the prophylaxis and treatment of thrombosis and embolism].
    BRETTLER A; HOEPFNER W
    Z Urol; 1951; 44(7):464-79. PubMed ID: 14867571
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prophylaxis of thrombosis with tromexan in closed fractures of the leg].
    GLOOR F; SIGG B
    Praxis; 1950 Sep; 39(39):839-40. PubMed ID: 14786168
    [No Abstract]   [Full Text] [Related]  

  • 16. Anticoagulant therapy with tromexan and marcoumar and determination of the prothrombin-proconvertin activity by a micro-method.
    IVERSEN T
    Acta Med Scand; 1956 Sep; 155(3):161-70. PubMed ID: 13361829
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of anticoagulants in dermatology; use of tromexan (ethyl ester of di-4-hydroxy-coumarinyl acetic acid) in ulcus cruris in dystrophy with thrombophlebitis and in related conditions].
    PANCONESI E
    Rass Dermatol Sifilogr; 1951; 4(2):74-105. PubMed ID: 14892261
    [No Abstract]   [Full Text] [Related]  

  • 18. A study on the toxicology and anticoagulant action of tromexan, a synthetic coumarin.
    GRUBER CM; LEE KS; LASZICZENKO T; GRUBER CM
    Arch Int Pharmacodyn Ther; 1951 Sep; 87(4):402-12. PubMed ID: 14895202
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical evaluation of dicumarinyl derivatives with a metabolic study of the radioactively labeled anticoagulants in animals.
    HAUSNER EP; SHAFER CL; CORSON M; JOHNSON O; TRUJILLO T; LANGHAM W
    Circulation; 1951 Feb; 3(2):171-81. PubMed ID: 14812645
    [No Abstract]   [Full Text] [Related]  

  • 20. [Metabolism in rats following prolonged administration of pelentan (di 4-hydroxycumarinyl-3-acetic acid ethylester); studies on anticoagulant substances V].
    HAIS IM; ZABRODSKY S
    Cas Lek Cesk; 1950 Oct; 89(40):1116-20. PubMed ID: 14772872
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.